Mainz Biomed (MYNZ) Competitors $2.09 -0.24 (-10.30%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$2.13 +0.04 (+2.15%) As of 05/21/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MYNZ vs. ELEV, NAII, DRRX, CMMB, CGTX, LPCN, JATT, BIVI, CVM, and MTEXShould you be buying Mainz Biomed stock or one of its competitors? The main competitors of Mainz Biomed include Elevation Oncology (ELEV), Natural Alternatives International (NAII), DURECT (DRRX), Chemomab Therapeutics (CMMB), Cognition Therapeutics (CGTX), Lipocine (LPCN), JATT Acquisition (JATT), BioVie (BIVI), CEL-SCI (CVM), and Mannatech (MTEX). These companies are all part of the "pharmaceutical products" industry. Mainz Biomed vs. Elevation Oncology Natural Alternatives International DURECT Chemomab Therapeutics Cognition Therapeutics Lipocine JATT Acquisition BioVie CEL-SCI Mannatech Elevation Oncology (NASDAQ:ELEV) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, community ranking, dividends, profitability, earnings, media sentiment, valuation and risk. Do institutionals and insiders hold more shares of ELEV or MYNZ? 83.7% of Elevation Oncology shares are owned by institutional investors. 8.1% of Elevation Oncology shares are owned by insiders. Comparatively, 18.2% of Mainz Biomed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community favor ELEV or MYNZ? Elevation Oncology received 25 more outperform votes than Mainz Biomed when rated by MarketBeat users. However, 73.68% of users gave Mainz Biomed an outperform vote while only 66.10% of users gave Elevation Oncology an outperform vote. CompanyUnderperformOutperformElevation OncologyOutperform Votes3966.10% Underperform Votes2033.90% Mainz BiomedOutperform Votes1473.68% Underperform Votes526.32% Which has more volatility & risk, ELEV or MYNZ? Elevation Oncology has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Is ELEV or MYNZ more profitable? Mainz Biomed's return on equity of 0.00% beat Elevation Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Elevation OncologyN/A -59.73% -40.05% Mainz Biomed N/A N/A N/A Does the media refer more to ELEV or MYNZ? In the previous week, Mainz Biomed had 5 more articles in the media than Elevation Oncology. MarketBeat recorded 8 mentions for Mainz Biomed and 3 mentions for Elevation Oncology. Mainz Biomed's average media sentiment score of 0.46 beat Elevation Oncology's score of -1.00 indicating that Mainz Biomed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elevation Oncology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Mainz Biomed 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend ELEV or MYNZ? Elevation Oncology presently has a consensus target price of $3.39, indicating a potential upside of 968.39%. Mainz Biomed has a consensus target price of $14.00, indicating a potential upside of 569.86%. Given Elevation Oncology's higher probable upside, research analysts clearly believe Elevation Oncology is more favorable than Mainz Biomed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elevation Oncology 0 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.30Mainz Biomed 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has stronger valuation & earnings, ELEV or MYNZ? Mainz Biomed has higher revenue and earnings than Elevation Oncology. Elevation Oncology is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElevation OncologyN/AN/A-$45.70M-$0.82-0.39Mainz Biomed$893.99K5.42-$26.30M-$65.60-0.03 SummaryMainz Biomed beats Elevation Oncology on 10 of the 16 factors compared between the two stocks. Get Mainz Biomed News Delivered to You Automatically Sign up to receive the latest news and ratings for MYNZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYNZ vs. The Competition Export to ExcelMetricMainz BiomedPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.85M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E Ratio-0.038.9226.8419.71Price / Sales5.42253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book0.196.466.794.50Net Income-$26.30M$143.98M$3.23B$248.18M7 Day Performance-7.93%2.03%1.53%0.20%1 Month Performance-34.48%4.11%10.05%12.37%1 Year Performance-91.07%-2.87%16.71%7.04% Mainz Biomed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYNZMainz Biomed2.2773 of 5 stars$2.09-10.3%$14.00+569.9%-91.0%$4.85M$893,991.00-0.0330Gap DownELEVElevation Oncology2.9143 of 5 stars$0.34+21.3%$3.39+887.7%-91.5%$20.30MN/A-0.4240Earnings ReportNAIINatural Alternatives International0.7244 of 5 stars$3.25flatN/A-49.7%$20.15M$121.85M-2.52290News CoverageAnalyst ForecastGap UpDRRXDURECT0.178 of 5 stars$0.65+3.0%N/A-54.4%$20.14M$2.03M-1.0680Gap DownHigh Trading VolumeCMMBChemomab Therapeutics3.3109 of 5 stars$1.40+2.2%$8.50+507.2%+68.3%$20.10MN/A-1.4020Earnings ReportCGTXCognition Therapeutics2.5451 of 5 stars$0.32-1.3%$6.13+1,808.1%-86.0%$19.90MN/A-0.3320LPCNLipocine1.5258 of 5 stars$3.71-7.0%$10.00+169.5%-44.6%$19.85M$3.67M-4.8810JATTJATT AcquisitionN/A$1.11-7.5%N/A-82.1%$19.15MN/A0.003High Trading VolumeBIVIBioVie2.7115 of 5 stars$1.03flat$3.00+191.3%+106.7%$19.12MN/A-0.1110CVMCEL-SCIN/A$0.21-6.1%N/A-88.5%$19.06MN/A-0.4443News CoverageHigh Trading VolumeMTEXMannatech0.4884 of 5 stars$9.93-5.9%N/A+34.0%$18.88M$117.87M-12.26250News CoverageAnalyst ForecastGap Up Related Companies and Tools Related Companies Elevation Oncology Alternatives Natural Alternatives International Alternatives DURECT Alternatives Chemomab Therapeutics Alternatives Cognition Therapeutics Alternatives Lipocine Alternatives JATT Acquisition Alternatives BioVie Alternatives CEL-SCI Alternatives Mannatech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MYNZ) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street see...Porter & Company | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MYNZ Stock Free MYNZ Stock Alerts